Celyad Oncology (LTS:0QFK) Tariff Resilience Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QFK Celyad Oncology SA LTS:0QFK
31 GF Score
Price €0.24
GF Value €0.67
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Tariff Resilience Score?

Celyad Oncology has the Tariff Resilience Score of 0, which implies that the company might have .

Celyad Oncology has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Celyad Oncology might have .

Celyad Oncology  (LTS:0QFK) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Celyad Oncology Tariff Resilience Score Related Terms

LTS:0QFK
31GF Score
Celyad Oncology SA LTS:0QFK
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celyad Oncology (LTS:0QFK) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of €0.24 is trading 64.8% below its estimated GF Value™ of €0.67. GuruFocus considers Celyad Oncology to be Possible Value Trap.

Key valuation signals for LTS:0QFK:

  • Tariff Resilience Score: 0
  • GF Value™: €0.67 vs. price of €0.24 (64.8% below fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the LTS:0QFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
31GF Score

Get the complete analysis for LTS:0QFK

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€0.67
GF Value